Do analysts prefer PBYI or RANI?

Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 1,058.94%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Is CMPX or RANI more profitable?

Compass Therapeutics' return on equity of -39.75% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -39.75% -35.29% Rani Therapeutics N/A -206.46% -83.95%

Which has stronger valuation & earnings, SNDL or RANI?

SNDL has higher revenue and earnings than Rani Therapeutics. SNDL is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SNDL $937.39M 0.39 -$11.29M -$0.03 N/A Rani Therapeutics $1.63M 57.38 -$29.67M -$0.41 N/A

Is SNDL or RANI more profitable?

Rani Therapeutics has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets SNDL -1.19% -1.02% -0.85% Rani Therapeutics N/A -206.46% -83.95%

Which has better earnings and valuation, AGMB or RANI?

AgomAb Therapeutics has higher earnings, but lower revenue than Rani Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A Rani Therapeutics $1.63M 57.38 -$29.67M -$0.41 N/A

Is AGMB or RANI more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Rani Therapeutics N/A -206.46% -83.95%

Is RANI or LRMR more profitable?

Larimar Therapeutics' return on equity of -134.14% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Larimar Therapeutics N/A -134.14% -96.00%

Rani Therapeutics (RANI) Competitors

$0.76 -0.02 (-2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$0.77 +0.01 (+1.85%)

As of 07:14 PM Eastern

Compare

RANI vs. PBYI, CMPX, SNDL, AGMB, and LRMR

Should you buy Rani Therapeutics stock or one of its competitors? MarketBeat compares Rani Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rani Therapeutics include Puma Biotechnology (PBYI), Compass Therapeutics (CMPX), SNDL (SNDL), AgomAb Therapeutics (AGMB), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry.

How does Rani Therapeutics compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Puma Biotechnology has a net margin of 10.69% compared to Rani Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Rani Therapeutics	N/A	-206.46%	-83.95%

Puma Biotechnology has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.79	$31.11M	$0.48	16.75
Rani Therapeutics	$1.63M	57.38	-$29.67M	-$0.41	N/A

Puma Biotechnology has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 1,058.94%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Rani Therapeutics' average media sentiment score of 0.00 beat Puma Biotechnology's score of -1.20 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Puma Biotechnology	Negative
Rani Therapeutics	Neutral

Summary

Puma Biotechnology beats Rani Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Compass Therapeutics presently has a consensus price target of $12.91, indicating a potential upside of 526.65%. Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 1,058.94%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Compass Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Rani Therapeutics has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	436.45	-$66.49M	-$0.41	N/A
Rani Therapeutics	$1.63M	57.38	-$29.67M	-$0.41	N/A

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Compass Therapeutics had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 2 mentions for Compass Therapeutics and 0 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.00 beat Compass Therapeutics' score of -1.87 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Compass Therapeutics	Very Negative
Rani Therapeutics	Neutral

Compass Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Compass Therapeutics' return on equity of -39.75% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Rani Therapeutics	N/A	-206.46%	-83.95%

Summary

Compass Therapeutics beats Rani Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to SNDL?

SNDL (NASDAQ:SNDL) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

30.2% of Rani Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, SNDL had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 1 mentions for SNDL and 0 mentions for Rani Therapeutics. SNDL's average media sentiment score of 0.00 equaled Rani Therapeutics'average media sentiment score.

Company	Overall Sentiment
SNDL	Neutral
Rani Therapeutics	Neutral

SNDL presently has a consensus price target of $5.00, indicating a potential upside of 249.65%. Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 1,058.94%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than SNDL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Rani Therapeutics has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SNDL	-1.19%	-1.02%	-0.85%
Rani Therapeutics	N/A	-206.46%	-83.95%

SNDL has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

SNDL has higher revenue and earnings than Rani Therapeutics. SNDL is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SNDL	$937.39M	0.39	-$11.29M	-$0.03	N/A
Rani Therapeutics	$1.63M	57.38	-$29.67M	-$0.41	N/A

Summary

Rani Therapeutics beats SNDL on 8 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Rani Therapeutics (NASDAQ:RANI) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

30.2% of Rani Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AgomAb Therapeutics currently has a consensus target price of $32.75, indicating a potential upside of 174.29%. Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 1,058.94%. Given Rani Therapeutics' higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, AgomAb Therapeutics had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 2 mentions for AgomAb Therapeutics and 0 mentions for Rani Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.50 beat Rani Therapeutics' score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
AgomAb Therapeutics	Positive
Rani Therapeutics	Neutral

AgomAb Therapeutics has higher earnings, but lower revenue than Rani Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Rani Therapeutics	$1.63M	57.38	-$29.67M	-$0.41	N/A

AgomAb Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Rani Therapeutics	N/A	-206.46%	-83.95%

Summary

AgomAb Therapeutics beats Rani Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Rani Therapeutics compare to Larimar Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rani Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

Rani Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 1,058.94%. Larimar Therapeutics has a consensus price target of $15.29, suggesting a potential upside of 315.37%. Given Rani Therapeutics' higher possible upside, equities analysts plainly believe Rani Therapeutics is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

In the previous week, Rani Therapeutics' average media sentiment score of 0.00 equaled Larimar Therapeutics'average media sentiment score.

Company	Overall Sentiment
Rani Therapeutics	Neutral
Larimar Therapeutics	Neutral

Larimar Therapeutics' return on equity of -134.14% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Larimar Therapeutics	N/A	-134.14%	-96.00%

Rani Therapeutics has higher revenue and earnings than Larimar Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	57.38	-$29.67M	-$0.41	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Summary

Larimar Therapeutics beats Rani Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Rani Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RANI vs. The Competition

Export

Metric	Rani Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$95.72M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-1.84	19.75	24.92	23.98
Price / Sales	57.38	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.22	8.29	10.79	6.50
Net Income	-$29.67M	$23.85M	$3.56B	$336.88M
7 Day Performance	-0.62%	5.21%	1.67%	-0.22%
1 Month Performance	-29.44%	2.19%	0.43%	0.77%
1 Year Performance	54.08%	60.99%	32.84%	31.57%

Rani Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RANI Rani Therapeutics	2.2386 of 5 stars	$0.76 -2.3%	$8.75 +1,058.9%	+54.4%	$95.72M	$1.63M	N/A	110
PBYI Puma Biotechnology	1.0241 of 5 stars	$7.07 -3.5%	N/A	+140.1%	$373.09M	$228.40M	14.73	200	Positive News
CMPX Compass Therapeutics	2.246 of 5 stars	$2.04 +0.5%	$12.91 +532.8%	-12.5%	$365.58M	$850K	N/A	20
SNDL SNDL	3.4556 of 5 stars	$1.43 +0.7%	$5.00 +249.7%	+12.0%	$365.50M	$677.32M	N/A	2,751	High Trading Volume
AGMB AgomAb Therapeutics	N/A	$10.00 +4.1%	$32.00 +220.0%	N/A	$362.37M	N/A	N/A	62	News Coverage Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RANI) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rani Therapeutics (RANI) Competitors

RANI vs. PBYI, CMPX, SNDL, AGMB, and LRMR

How does Rani Therapeutics compare to Puma Biotechnology?

Summary

How does Rani Therapeutics compare to Compass Therapeutics?

Summary

How does Rani Therapeutics compare to SNDL?

Summary

How does Rani Therapeutics compare to AgomAb Therapeutics?

Summary

How does Rani Therapeutics compare to Larimar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rani Therapeutics (RANI) Competitors

RANI vs. PBYI, CMPX, SNDL, AGMB, and LRMR

How does Rani Therapeutics compare to Puma Biotechnology?

Is PBYI or RANI more profitable?

Which has preferable valuation and earnings, PBYI or RANI?

Which has more volatility & risk, PBYI or RANI?

Do institutionals & insiders have more ownership in PBYI or RANI?

Do analysts prefer PBYI or RANI?

Does the media favor PBYI or RANI?

Summary

How does Rani Therapeutics compare to Compass Therapeutics?

Do analysts prefer CMPX or RANI?

Which has stronger valuation & earnings, CMPX or RANI?

Do institutionals and insiders have more ownership in CMPX or RANI?

Does the media favor CMPX or RANI?

Which has more risk and volatility, CMPX or RANI?

Is CMPX or RANI more profitable?

Summary

How does Rani Therapeutics compare to SNDL?

Do institutionals & insiders believe in SNDL or RANI?

Does the media prefer SNDL or RANI?

Do analysts prefer SNDL or RANI?

Is SNDL or RANI more profitable?

Which has more risk & volatility, SNDL or RANI?

Which has stronger valuation & earnings, SNDL or RANI?

Summary

How does Rani Therapeutics compare to AgomAb Therapeutics?

Do insiders & institutionals believe in AGMB or RANI?

Do analysts prefer AGMB or RANI?

Does the media favor AGMB or RANI?

Which has better earnings and valuation, AGMB or RANI?

Is AGMB or RANI more profitable?

Summary

How does Rani Therapeutics compare to Larimar Therapeutics?

Do insiders and institutionals believe in RANI or LRMR?

Which has more volatility and risk, RANI or LRMR?

Do analysts prefer RANI or LRMR?

Does the media refer more to RANI or LRMR?

Is RANI or LRMR more profitable?

Which has stronger valuation and earnings, RANI or LRMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools